DK3371190T3 - Heterocykliske forbindelser som pi3k-gamma-inhibitorer - Google Patents

Heterocykliske forbindelser som pi3k-gamma-inhibitorer Download PDF

Info

Publication number
DK3371190T3
DK3371190T3 DK16805238.9T DK16805238T DK3371190T3 DK 3371190 T3 DK3371190 T3 DK 3371190T3 DK 16805238 T DK16805238 T DK 16805238T DK 3371190 T3 DK3371190 T3 DK 3371190T3
Authority
DK
Denmark
Prior art keywords
pi3k
heterocyclic compounds
gamma inhibitors
gamma
inhibitors
Prior art date
Application number
DK16805238.9T
Other languages
Danish (da)
English (en)
Inventor
Artem Shvartsbart
Stacey Shepard
Andrew P Combs
Lixin Shao
Nikoo Falahatpisheh
Ge Zou
Andrew W Buesking
Richard B Sparks
Eddy W Yue
Ravi Jalluri
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Application granted granted Critical
Publication of DK3371190T3 publication Critical patent/DK3371190T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK16805238.9T 2015-11-06 2016-11-04 Heterocykliske forbindelser som pi3k-gamma-inhibitorer DK3371190T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562252050P 2015-11-06 2015-11-06
PCT/US2016/060468 WO2017079519A1 (en) 2015-11-06 2016-11-04 Heterocyclic compounds as pi3k-gamma inhibitors

Publications (1)

Publication Number Publication Date
DK3371190T3 true DK3371190T3 (da) 2022-05-23

Family

ID=57460598

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16805238.9T DK3371190T3 (da) 2015-11-06 2016-11-04 Heterocykliske forbindelser som pi3k-gamma-inhibitorer

Country Status (19)

Country Link
US (4) US10065963B2 (enExample)
EP (2) EP3371190B1 (enExample)
JP (1) JP6854817B2 (enExample)
AR (1) AR106595A1 (enExample)
CY (1) CY1125245T1 (enExample)
DK (1) DK3371190T3 (enExample)
ES (1) ES2915550T3 (enExample)
HR (1) HRP20220599T1 (enExample)
HU (1) HUE059324T2 (enExample)
LT (1) LT3371190T (enExample)
MA (1) MA43169B1 (enExample)
MD (1) MD3371190T2 (enExample)
PL (1) PL3371190T3 (enExample)
PT (1) PT3371190T (enExample)
RS (1) RS63359B1 (enExample)
SI (1) SI3371190T1 (enExample)
SM (1) SMT202200250T1 (enExample)
TW (2) TWI744256B (enExample)
WO (1) WO2017079519A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170333435A1 (en) 2014-11-06 2017-11-23 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
EP3215509B1 (en) 2014-11-06 2020-02-26 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
PT3215511T (pt) 2014-11-06 2024-05-22 Bial R&D Invest S A Pirazolo(1,5-a)pirimidinas substituídas e a sua utilização no tratamento de distúrbios médicos
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
AR106595A1 (es) 2015-11-06 2018-01-31 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
EP3792256B1 (en) 2016-01-05 2024-10-23 Incyte Corporation Pyridine compounds as pi3k-gamma inhibitors
MA43677A (fr) * 2016-02-25 2018-11-28 Asceneuron Sa Inhibiteurs de glycosidases
MX2018012208A (es) 2016-04-06 2019-03-28 Lysosomal Therapeutics Inc Compuestos a base de imidazo [1,5-a] pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos.
EP3440080A4 (en) 2016-04-06 2020-01-22 Lysosomal Therapeutics Inc. PYRAZOLO [1,5-A] PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
WO2017176962A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics, Inc. Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
US11345698B2 (en) 2016-05-05 2022-05-31 Bial—R&D Investments, S.A. Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders
JP7164774B2 (ja) * 2016-05-05 2022-11-02 ビアル－アール・アンド・ディ・インベストメンツ・ソシエダーデ・アノニマ 置換イミダゾ［１，２－ｂ］ピリダジン、置換イミダゾ［１，５－ｂ］ピリダジン、関連化合物、および医学的障害の治療におけるその使用
TW201803871A (zh) 2016-06-24 2018-02-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
EP3658148B1 (en) * 2017-07-28 2024-07-10 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
MX2020003862A (es) 2017-10-18 2020-08-13 Incyte Corp Derivados condensados de imidazol sustituidos por grupos hidroxi terciarios como inhibidores de fosfoinositido 3-cinasas gamma (pi3k-gamma).
TW201927777A (zh) * 2017-12-19 2019-07-16 大陸商基石藥業（蘇州）有限公司 Ido抑制劑
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
BR112021019070A2 (pt) 2019-03-26 2022-02-15 Ventyx Biosciences Inc Ligantes de pseudoquinase tyk2
US12404260B2 (en) 2019-04-11 2025-09-02 Janssen Pharmaceutica Nv Pyridine rings containing derivatives as MALT1 inhibitors
EP3980010A4 (en) 2019-06-04 2023-06-07 Arcus Biosciences, Inc. 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS
CA3139365A1 (en) * 2019-06-06 2020-12-10 Aligos Therapeutics, Inc. Heterocyclic compounds
IL292785B2 (en) 2019-11-08 2025-09-01 Ventyx Biosciences Inc Tyk2 pseudokinase ligands
CN116348453B (zh) * 2021-04-25 2025-07-04 烨辉医药科技(上海)有限公司 杂芳族甲酰胺化合物及其用途
WO2025146216A1 (zh) * 2024-01-05 2025-07-10 成都赜灵生物医药科技有限公司 六并五氮杂环酰胺类化合物及其用途

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4269846A (en) 1979-10-29 1981-05-26 Usv Pharmaceutical Corporation Heterocyclic compounds useful as anti-allergy agents
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
BR9912938B1 (pt) 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0011092D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (III)
ES2225624T3 (es) 2000-06-28 2005-03-16 Smithkline Beecham Plc Procedimiento de molienda por via humeda.
ATE420879T1 (de) 2001-09-19 2009-01-15 Aventis Pharma Sa Indolizine als kinaseproteinhemmer
FR2831536A1 (fr) 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
BR0213562A (pt) 2001-10-26 2004-08-31 Aventis Pharma Inc Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
US7973031B2 (en) 2001-10-30 2011-07-05 Novartis Ag Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
DE10207843A1 (de) 2002-02-15 2003-09-04 Schering Ag Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7186832B2 (en) 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
WO2004078943A2 (en) 2003-03-04 2004-09-16 California Institute Of Technology Alternative heterocycles for dna recognition
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US7511145B2 (en) 2003-08-01 2009-03-31 Genelabs Technologies, Inc. Bicyclic heteroaryl derivatives
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
WO2005118580A2 (en) 2004-05-12 2005-12-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Tricyclic compounds as inhibitors of the hypoxic signaling pathway
JP2008520612A (ja) 2004-11-24 2008-06-19 ノバルティス アクチエンゲゼルシャフト ＪＡＫ阻害剤およびＢｃｒ−Ａｂｌ、Ｆｌｔ−３、ＦＡＫまたはＲＡＦキナーゼ阻害剤のうち少なくとも１個の組合せ
EP2388263A1 (en) 2005-08-04 2011-11-23 Sirtris Pharmaceuticals, Inc. Imidazo[2,1-b]thiazole derivatives as sirtuin modulators
JP2009507032A (ja) 2005-09-02 2009-02-19 アボット・ラボラトリーズ 新規なイミダゾ系複素環
CN102775396B (zh) 2005-11-08 2014-10-08 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的杂环调控剂
PT1966202E (pt) 2005-12-13 2012-01-03 Incyte Corp Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase
BRPI0713328A2 (pt) 2006-06-22 2012-10-30 Biovitrum Ab derivados de piridina e pirazina como inibidores de cinase mnk
WO2009005551A2 (en) 2007-03-27 2009-01-08 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
DE102007035333A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
CA2709883A1 (en) 2007-12-19 2009-06-25 The Scripps Research Institute Benzimidazoles and analogs as rho kinase inhibitors
AP2010005308A0 (en) 2008-01-15 2010-06-30 Siga Technologies Inc Antiviral drugs for treatment of arenavirus infection
WO2009133127A1 (en) 2008-04-30 2009-11-05 Merck Serono S.A. Fused bicyclic compounds and use thereof as pi3k inhibitors
US8362268B2 (en) 2008-05-30 2013-01-29 University Of Notre Dame Du Lac Anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria
EP2358202B1 (en) 2008-11-03 2016-06-15 Merck Sharp & Dohme Corp. Benzimidazole and aza-benzimidazole carboxamides
TW201028399A (en) 2008-11-27 2010-08-01 Shionogi & Co Pyrimidine derivative and pyridine derivative both having pi3k inhibitory activity
GB0822981D0 (en) 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
EP2401273A1 (en) 2009-02-27 2012-01-04 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
TW201100429A (en) 2009-05-22 2011-01-01 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
ME01838B (me) 2009-06-29 2014-12-20 Lncyte Holdings Corp Pirimidinoni kao inhibitori pi3k
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TW201130842A (en) 2009-12-18 2011-09-16 Incyte Corp Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
WO2011099832A2 (en) 2010-02-12 2011-08-18 Crystalgenomics, Inc. Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
MX354212B (es) 2010-03-10 2018-02-19 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
EP2552208A4 (en) 2010-03-31 2014-07-09 Glaxo Group Ltd IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS
CA2796311A1 (en) 2010-04-14 2011-10-20 Incyte Corporation Fused derivatives as pi3k.delta. inhibitors
EP2575866A4 (en) 2010-05-24 2013-10-16 Presidio Pharmaceuticals Inc HCV NS5A INHIBITORS
WO2011149874A2 (en) 2010-05-26 2011-12-01 Schering Corporation N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
BR112013009166A2 (pt) 2010-10-13 2016-07-26 Millennium Pharm Inc heteroarilas e uso das mesmas.
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
AR084032A1 (es) 2010-11-30 2013-04-17 Takeda Pharmaceutical Compuesto biciclico
JP5961187B2 (ja) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ阻害剤としてのｎ−（１−（置換フェニル）エチル）−９ｈ−プリン−６−アミン
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US8673905B2 (en) 2011-03-17 2014-03-18 Hoffmann-La Roche Inc. Imidazo pyrazines
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
WO2012143796A2 (en) 2011-04-21 2012-10-26 Institut Pasteur Korea Anti-inflammation compounds
EP2718279B1 (en) 2011-06-09 2016-08-10 Rhizen Pharmaceuticals SA Novel compounds as modulators of gpr-119
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
SI3513793T1 (sl) 2011-09-02 2021-07-30 Incyte Holdings Corporation Heterociklilamini kot zaviralci PI3K
WO2013129674A1 (ja) 2012-03-01 2013-09-06 学校法人兵庫医科大学 新規ベンズイミダゾール誘導体及びその用途
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US8940742B2 (en) * 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
JP6217629B2 (ja) 2012-05-31 2017-10-25 住友化学株式会社 縮合複素環化合物
WO2014009295A1 (en) 2012-07-13 2014-01-16 Ucb Pharma S.A. Imidazopyridine derivatives as modulators of tnf activity
BR112015009942A2 (pt) 2012-11-01 2017-07-11 Incyte Corp derivados de tiofeno fundidos tricíclicos como inibidores de jak
TWI687220B (zh) 2013-03-01 2020-03-11 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
WO2014149207A2 (en) 2013-03-15 2014-09-25 Dow Agrosciences Llc Benzimidazole-based insecticidal compositions and related methods
WO2014153529A1 (en) 2013-03-22 2014-09-25 The Scripps Research Institute Substituted benzimidazoles as nociceptin receptor modulators
WO2014182954A1 (en) 2013-05-08 2014-11-13 Colorado Seminary, Which Owns And Operates The University Of Denver Antibiotic and anti-parasitic agents that modulate class ii fructose 1,6-bisphosphate aldolase
WO2014186706A1 (en) 2013-05-17 2014-11-20 Incyte Corporation Bipyrazole derivatives as jak inhibitors
EP4570313A2 (en) 2013-07-17 2025-06-18 Otsuka Pharmaceutical Co., Ltd. Cyanotriazole compounds
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
HRP20201887T1 (hr) 2014-04-08 2021-02-05 Incyte Corporation LIJEČENJE B-STANIČNIH MALIGNITETA S KOMBINACIJOM INHIBITORA JAK i PI3K
EP2930048A1 (en) 2014-04-10 2015-10-14 Johnson Controls Automotive Electronics SAS Head up display projecting visual information onto a screen
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
JP6660060B2 (ja) 2014-09-16 2020-03-04 セルジーン クオンティセル リサーチ，インク． ヒストンデメチラーゼ阻害剤
WO2016054491A1 (en) * 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MA40933A (fr) 2014-11-11 2017-09-19 Piqur Therapeutics Ag Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
AR106595A1 (es) 2015-11-06 2018-01-31 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
EP3792256B1 (en) 2016-01-05 2024-10-23 Incyte Corporation Pyridine compounds as pi3k-gamma inhibitors
TW201803871A (zh) 2016-06-24 2018-02-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物

Also Published As

Publication number Publication date
US20230009843A1 (en) 2023-01-12
WO2017079519A1 (en) 2017-05-11
HRP20220599T1 (hr) 2022-06-24
MA43169A (fr) 2018-09-12
TW201726679A (zh) 2017-08-01
RS63359B1 (sr) 2022-07-29
US11773102B2 (en) 2023-10-03
EP3371190A1 (en) 2018-09-12
US20190062336A1 (en) 2019-02-28
US11091491B2 (en) 2021-08-17
SI3371190T1 (sl) 2022-08-31
TWI744256B (zh) 2021-11-01
JP2018532760A (ja) 2018-11-08
US20200031837A1 (en) 2020-01-30
JP6854817B2 (ja) 2021-04-07
EP4086259A1 (en) 2022-11-09
SMT202200250T1 (it) 2022-07-21
ES2915550T3 (es) 2022-06-23
EP3371190B1 (en) 2022-03-30
MD3371190T2 (ro) 2022-09-30
CY1125245T1 (el) 2025-03-28
PT3371190T (pt) 2022-07-08
LT3371190T (lt) 2022-08-10
PL3371190T3 (pl) 2022-11-07
AR106595A1 (es) 2018-01-31
US10065963B2 (en) 2018-09-04
HUE059324T2 (hu) 2022-11-28
US10472368B2 (en) 2019-11-12
MA43169B1 (fr) 2022-05-31
TWI824309B (zh) 2023-12-01
TW202204362A (zh) 2022-02-01
US20170129899A1 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
CY2024003I2 (el) Ενωσεις χρησιμες ως αναστολεις κινασης
DK3442980T3 (da) Heterocykliske forbindelser som ret-kinase-hæmmere
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
DK3704120T3 (da) Heterocykliske forbindelser som prmt5-inhibitorer
DK3377488T3 (da) Heterocykliske forbindelser som immunomodulatorer
DK3684767T3 (da) Heterocykliske forbindelser som pad-inhibitorer
DK3472167T3 (da) Heterocykliske forbindelser som immunomodulatorer
DK3298002T3 (da) Heterocykliske amider som kinasehæmmere
IL250923A0 (en) Novel compounds as rearranged during transfection (ret) inhibitors
DK3277677T3 (da) 1-cyano-pyrrolidinforbindelser som usp30-hæmmere
DK3365334T3 (da) Benzolactamforbindelser som proteinkinaseinhibitorer
DK3464271T3 (da) Pyrazolderivater som plasma-kallikreininhibitorer
LT3303334T (lt) Tirozinkinazės inhibitoriai
DK3436444T3 (da) Heterocyklisk forbindelse
DK3302448T3 (da) Erstattede heterocyclylafledninger som cdk-inhibitore
LT3371171T (lt) Ret inhibitoriai
DK3324977T3 (da) Benzodiazepinderivater som rsv-inhibitorer
PL3209656T3 (pl) Związki indolo-karboksyamidu użyteczne jako inhibitory kinazy
DK3498693T3 (da) Heterocyklisk forbindelse
DK3224256T3 (da) N-((het)arylmethyl)-heteroaryl-carboxamid-forbindelser som plasma kallikrein-inhibitorer
DK3105218T3 (da) Cyclopropylaminer som lsd1-inhibitorer
DK3105226T3 (da) Cyclopropylaminer som lsd1-inhibitorer
DK3357919T3 (da) Aromatiske heterocykliske forbindelser som antiinflammatoriske forbindelser
DK3271349T3 (da) Benzimidazolederivater som bromodomain-inhibitorer
EP3313828A4 (en) METALLO-BETA-Lactamase INHIBITORS